Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
13 Dezember 2023 - 3:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of December 2023
Commission
File Number 001-41231
TC
BIOPHARM (HOLDINGS) PLC
(Translation
of registrant’s name into English)
Maxim
1, 2 Parklands Way
Holytown,
Motherwell, ML1 4WR
Scotland,
United Kingdom
+44
(0) 141 433 7557
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ ☐
On
December 13, 2023, TC Biopharm (Holdings) PLC issued a press release, a copy of which is attached hereto as Exhibit 99.1.
Incorporation
by Reference
This
Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into the
Registrant’s Registration Statement on Form F-1 filed with the Securities and Exchange
Commission on August 28, 2023 (Registration file number 333-274244), the Registrant’s Registration Statement on Form F-3 filed
with the Securities and Exchange Commission on September 29, 2023 (Registration file number 333-274778),
the Registrant’s Registration Statement on Form F-1 filed with the Securities and
Exchange Commission on March 23, 2023 (Registration file number 333-270808 and the Registrant’s Registration Statement on
Form F-1 filed with the Securities and Exchange Commission on December 12, 2022 (Registration
file number 333-268755), to be a part thereof from the date on which this report is submitted, to the extent not superseded by
documents or reports subsequently filed or furnished.
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
TC
BIOPHARM (HOLDINGS) PLC |
|
|
|
|
By: |
/s/
Martin Thorp |
|
Name: |
Martin Thorp |
|
Title: |
Chief Financial Officer |
Date:
December 13, 2023
Exhibit
99.1
TC
BioPharm Announces Plan to Implement ADS Ratio Change
EDINBURGH,
Scotland, December 13, 2023 -- TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP)
a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today
that it will change its ratio of its American Depositary Shares (“ADSs”) to ordinary shares from one (1) ADS representing
one (1) ordinary share to one ADS representing twenty (20) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change
is expected to become effective on or about December 15, 2023, U.S. Eastern Time (the “ Effective Date”).
For
the ADS holders, the ADS Ratio Change will have the same effect as a one-for-20 reverse ADS split. The ADS Ratio Change will have no
impact on the Company’s underlying ordinary shares, and no ordinary shares will be issued or cancelled in connection with the ADS
Ratio Change. On the Effective Date, holders of the ADSs will be required to surrender and exchange every twenty (20) ADSs then held
for one (1) new ADS. The Bank of New York Mellon, as the depositary bank for the Company’s ADS program (the “Depositary”),
will arrange for the exchange. The ADSs will continue to be traded on Nasdaq Capital Market under the symbol “TCBP.”
No
fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will
be aggregated and sold by the Depositary and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction
of fees, taxes and expenses) will be distributed to the applicable ADS holders by the Depositary.
As
a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance
that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous’ ADS trading
price prior to the change.
About
TC BioPharm (Holdings) PLC
TC
BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell
therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring
immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy
and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify,
target and eradicate both liquid and solid tumors in cancer.
TC
BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies
in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line
- Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company’s proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio in the use of CARs with gamma-delta T cells and owns our manufacturing facility
to maintain cost and product quality controls.
Contact:
Chris
Camarra
EVP
Communications
c.camarra@tcbiopharm.com
TC BioPharm (NASDAQ:TCBP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
TC BioPharm (NASDAQ:TCBP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024